Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Lung-202: pumitamig versus pembrolizumab in first-line PD-L1-high advanced non-small cell lung cancer
2025-523586-18-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial of pumitamig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival and Overall survival. Planned start Jun 2026; status: authorised.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523586-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523586-18-00.